RT Journal Article
SR Electronic
T1 Characterising within-hospital SARS-CoV-2 transmission events: a retrospective analysis integrating epidemiological and viral genomic data from a UK tertiary care setting across two pandemic waves
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.15.21260537
DO 10.1101/2021.07.15.21260537
A1 Benjamin B. Lindsey
A1 Ch. Julián Villabona-Arenas
A1 Finlay Campbell
A1 Alexander J. Keeley
A1 Matthew D. Parker
A1 Dhruv R Shah
A1 Helena Parsons
A1 Peijun Zhang
A1 Nishchay Kakkar
A1 Marta Gallis
A1 Benjamin H. Foulkes
A1 Paige Wolverson
A1 Stavroula F Louka
A1 Stella Christou
A1 Amy State
A1 Katie Johnson
A1 Mohammad Raza
A1 Sharon Hsu
A1 Thibaut Jombart
A1 Anne Cori
A1 Sheffield COVID-19 Genomics Group
A1 The COVID-19 Genomics UK (COG-UK) consortium
A1 CMMID COVID-19 working group
A1 Cariad M. Evans
A1 David G. Partridge
A1 Katherine E. Atkins
A1 Stéphane Hué
A1 Thushan I. de Silva
YR 2021
UL http://medrxiv.org/content/early/2021/07/19/2021.07.15.21260537.abstract
AB Objectives To characterise within-hospital SARS-CoV-2 transmission across two waves of the COVID-19 pandemic.Design A retrospective Bayesian modelling study to reconstruct transmission chains amongst 2181 patients and healthcare workers using combined viral genomic and epidemiological data.Setting A large UK NHS Trust with over 1400 beds and employing approximately 17,000 staff.Participants 780 patients and 522 staff testing SARS-CoV-2 positive between 1st March 2020 and 25th July 2020 (Wave 1); and 580 patients and 299 staff testing SARS-CoV-2 positive between 30th November 2020 and 24th January 2021 (Wave 2).Main outcome measures Transmission pairs including who-infected-whom; location of transmission events in hospital; number of secondary cases from each individual, including differences in onward transmission from community and hospital onset patient cases.Results Staff-to-staff transmission was estimated to be the most frequent transmission type during Wave 1 (31.6% of observed hospital-acquired infections; 95% CI 26.9 to 35.8%), decreasing to 12.9% (95% CI 9.5 to 15.9%) in Wave 2. Patient-to-patient transmissions increased from 27.1% in Wave 1 (95% CI 23.3 to 31.4%) to 52.1% (95% CI 48.0 to 57.1%) in Wave 2, to become the predominant transmission type. Over 50% of hospital-acquired infections were concentrated in 8/120 locations in Wave 1 and 10/93 locations in Wave 2. Approximately 40% to 50% of hospital-onset patient cases resulted in onward transmission compared to less than 4% of definite community-acquired cases.Conclusions Prevention and control measures that evolved during the COVID-19 pandemic may have had a significant impact on reducing infections between healthcare workers, but were insufficient during the second wave to prevent a high number of patient-to-patient transmissions. As hospital-acquired cases appeared to drive most onward transmissions, more frequent and rapid identification and isolation of these cases will be required to break hospital transmission chains in subsequent pandemic waves.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) and Genome Research Limited, operating as the Wellcome Sanger Institute. MDP and DW are funded by the NIHR Sheffield Biomedical Research Centre (BRC - IS-BRC-1215-20017). TIdS is supported by a Wellcome Trust Intermediate Clinical Fellowship (110058/Z/15/Z). CJVA and KEA were funded by an ERC Starting Grant (action number 757688). This study is partially funded by the NIHR Health Protection Research Unit in Modelling and Health Economics, a partnership between Public Health England, Imperial College London and LSHTM (grant code NIHR200908); and acknowledges funding from the MRC Centre for Global Infectious Disease Analysis (reference MR/R015600/1), jointly funded by the UK MRC and the UK Foreign, Commonwealth & Development Office (FCDO), under the MRC/FCDO Concordat agreement and is also part of the EDCTP2 programme supported by the European Union. Disclaimer: The views expressed are those of the author(s) and not necessarily those of the NIHR, Public Health England or the Department of Health and Social Care. The funders had no role in study design, data collection, data analysis, data interpretation or writing of the report.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval for the study was obtained from the UK Health Research Authority (IRAS 281918), with sequencing performed according to The COVID-19 Genomics UK (COG-UK) study protocol approved by the Public Health England Research Ethics Governance Group (R&D NR0195).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon request however a data sharing agreement is required